Gillian Sandler brings 25 years of experience as an entrepreneur, CEO, Chairman, investor, research analyst, corporate strategist and philanthropist in the U.S. and internationally, across multiple economic and market cycles, restructurings, and stages of growth and financing.
She serves as a member of:
Lead investor and Board Member in AZTherapies, a clinical stage biopharma company focused on accelerating treatments to extend brain health and prevent neurodegeneration, with a focus on targeting neuroinflammation, and the brain’s immune system [microglial cells, mast cells, macrophages].
Lead investor and Board Member in Mymee, a pioneer in the autoimmune disease industry. Mymee’s platform allows people with active disease flares from Lupus, RA, Long COVID, MS or a multiple autoimmune disease diagnosis, to find the correlations between triggers and symptoms, and reduce and better control their disease flares.
She previously was a lead investor and served on the Board of Directors of Invicro [sold to Konica Minolta 4Q/17) after having co-led the financing for the acquisition of Molecular Neuro Imaging (MNI). Invicro’s innovative imaging advancements in the field of Alzheimer’s and cancer immunotherapy helped to transform the accuracy, cost and time for biotech and pharma companies to conduct R&D and clinical research. Lowering the investment and time hurdles of drug R&D and clinical research was an essential step for more competition to enter the CNS therapeutics market and break down the industry barriers that had kept the drug pipeline diversity low, prices high and slowed patient access to new drugs.
She also serves on the Advisory Board to McKinley Capital Management. In her role as advisor, she helped to architect the McKinley Global Healthcare Transformation public market portfolio launched in 2019. The global diversified portfolio invests in the publicly traded growth companies leading the improvement and transformation of healthcare in local markets globally.
Other private investments include Linus Bio, a precision exposome sequencing company and Envisagenics, a drug discovery company focused on transcriptomics (splicing errors). Advancing the fields of exposome diagnostics and transcriptomics are both critically important to generating new approaches to treatments for complex autoimmune and neurological diseases that are highly variable by person, and not attributable to a single genetic mutation.
She currently serves on the Board of Trustees of the Columbia Zuckerman Mind, Brain, Behavior Institute.
Her first role in helping to advance research and care in the field of brain health was 15 years ago serving on the Board of the Pediatric Brain Injury (PBI) Program, U of Miami School of Medicine (the pediatric arm of The Miami Project) a leading center for the prevention, research, and rehabilitation of children with severe brain injury.
Her experience in the consumer health space includes her role 2002-2012 as the CEO & Chairman of Todobebe, Inc (sold to Entravision (EVC) 2012), and her experience in entrepreneurship in mobile tech, software and AI includes being the founding CEO of one of the first mobile software tech start up in Europe in 2000 [Wallaware, Inc].
During her tenure at Todobebe, she received the 1st Prevention Pioneer Award for Changing Health Disparity among underserved populations by former U.S. Surgeon General Richard Carmona, and was nominated as a top CEO of Hispanic Media companies by Hispanic Ad (2010 & ‘11). The company led collaborations with HHS, the CDC, USDA, Walmart, Molina Healthcare, and multiple hospitals across the U.S. to shift focus of consumers from treatment to disease prevention. Founded in 1999 as the first parenting website for Spanish & Portuguese speakers in the U.S. and Latin America, Todobebe became a household consumer brand across Broadcast TV (over 250 episodes of “Todobebe” and “Viva La Familia”), Digital, Radio, Events, Marketing, Research, Mobile, Publishing, and Licensing, and multi-year partnerships with the largest TV, retail and consumer brands serving the Hispanic market [such as Univision, Telemundo-NBC, Televisa, Walmart, Procter & Gamble].
She also served from 2001 to 2008 on the Board of Directors of Medcenter Solutions, when it was the leading CRM Pharmaceutical marketing and Continuing Medical Education Company serving Brazil, Argentina and Mexico.
During her tenure as the founding CEO of Wallaware, it was ranked as a top-4 emerging mobile technology company in Europe by Tornado Insider (‘00), and was selected by IBM as its first “Blue Light” case study supporting emerging mobile tech companies (‘01). The company’s data platform, API and SDK enabled telco’s to securely control, manage, analyze, develop use cases, drive apps development, and monetize consumer and enterprise mobile data use.
Positions prior to 2000 included:
Strategist with AppNet/CMRC where her role was to advise Fortune 500 corporations across consumer products, healthcare, finance, media and publishing on how to leverage their assets to prepare for long term growth in a rapidly changing technology, telecom & media landscape – build/buy/partner, 10 year business plan development, deal structures, valuation, negotiation.
Equity analyst at JPMorgan, on the team that earned the #1 Institutional Investor ranking for the Telecom Industry in Latin America. She covered privatizations and IPOs across the region, and wrote extensively on the future of the emerging wireless industry. JP Morgan Global Credit analyst developing credit ratings and recommendations behind loans to the largest U.S. retailers during a period of rapid industry transition and high number of bankruptcies (1995).
In October 2012 and February 2013 she completed the Executive Programs “FutureMed” and “Singularity” at Singularity University at NASA/Ames in Mountain View California.
At JPMorgan, she completed the Management Services training program, the Equity Research training program, and received her Series 7 and Series 63 certifications.
Gillian received a BA and Certificate for International Relations with a focus on Developing Economies from Wesleyan University (CT), and ran for the University Track & Cross Country teams.
Prior to University, she worked for a semester at JPL/NASA doing programming (IDL) and satellite industry research for the Chief Scientist of MISR, Dr. David Diner, and did a one month internship studying Dolphins at the Kewalo Basin Marine Mammal Laboratory, Oahu, Hawaii.